Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Model scores of the 29,894 trials active now.

Model score 52% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (544 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: alzheimerpflong termextensionterm safety
  Phrases that lowered it: patientslabel randomizedweeksevaluate theto evaluate
• Sponsor's past termination rate: 16.0% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 367 (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 974 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 50 (raises risk) · Who can join
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Maximum age: 90 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 5 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease NCT01193608 · started 2010 · scored riskier than 99% of active trials completed
• Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab NCT00916617 · started 2009 · scored riskier than 91% of active trials terminated
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease NCT00937352 · started 2009 · scored riskier than 99% of active trials terminated
• Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease NCT04886063 · started 2021 · scored riskier than 99% of active trials terminated
• This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease NCT01676935 · started 2012 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.